Arch Biopartners acquires and develops products and technology for sale to pharmaceutical and industrial companies.
Arch Biopartners has raised $432K in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2026.
Arch Biopartners's investors include National Research Council of Canada Industrial Research Assistance Program, Canadian Institutes of Health Research.
Arch Biopartners is headquartered in Toronto, Canada.
Arch Biopartners acquires and develops products and technology for sale to pharmaceutical and industrial companies.
Arch Biopartners is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Arch Biopartners — Funding & Investors." VCBacked, March 30, 2026, https://www.vcbacked.co/company/arch-biopartners. Accessed August 14, 2026.
VCBacked. (2026). Arch Biopartners — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/arch-biopartners
{{cite web |title=Arch Biopartners — Funding & Investors |url=https://www.vcbacked.co/company/arch-biopartners |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated